BR112015021884A8 - vetores de plasmídeo recombinantes, partícula viral avv ou pluralidade de partículas virais, seus métodos de produção e seus usos, e composição farmacêutica - Google Patents
vetores de plasmídeo recombinantes, partícula viral avv ou pluralidade de partículas virais, seus métodos de produção e seus usos, e composição farmacêutica Download PDFInfo
- Publication number
- BR112015021884A8 BR112015021884A8 BR112015021884A BR112015021884A BR112015021884A8 BR 112015021884 A8 BR112015021884 A8 BR 112015021884A8 BR 112015021884 A BR112015021884 A BR 112015021884A BR 112015021884 A BR112015021884 A BR 112015021884A BR 112015021884 A8 BR112015021884 A8 BR 112015021884A8
- Authority
- BR
- Brazil
- Prior art keywords
- avv
- pharmaceutical composition
- viral
- recombinant plasmid
- production methods
- Prior art date
Links
- 239000002245 particle Substances 0.000 title 2
- 230000003612 virological effect Effects 0.000 title 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000013600 plasmid vector Substances 0.000 title 1
- 239000013598 vector Substances 0.000 abstract 2
- 239000013603 viral vector Substances 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 1
- 239000000945 filler Substances 0.000 abstract 1
- 239000012535 impurity Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
- C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
Abstract
resumo patente de invenção: "vetores compreendendo sequências de polinucleotídeos de stuffer/agente de enchimento e métodos de uso". a presente invenção refere-se a vetores virais recombinantes, tais como vetores aav projetados com cassetes de expressão, que abordam a capacidade de empacotamento natural do vírus, tal como aav. os vetores virais recombinantes reduzem as impurezas de dna do plasmídeo residual.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361799342P | 2013-03-15 | 2013-03-15 | |
PCT/US2014/028911 WO2014144486A2 (en) | 2013-03-15 | 2014-03-14 | Vectors comprising stuffer/filler polynucleotide sequences and methods of use |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112015021884A2 BR112015021884A2 (pt) | 2017-07-18 |
BR112015021884A8 true BR112015021884A8 (pt) | 2019-11-26 |
Family
ID=51538331
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015021884A BR112015021884A8 (pt) | 2013-03-15 | 2014-03-14 | vetores de plasmídeo recombinantes, partícula viral avv ou pluralidade de partículas virais, seus métodos de produção e seus usos, e composição farmacêutica |
Country Status (13)
Country | Link |
---|---|
US (1) | US11427835B2 (pt) |
EP (1) | EP2970943A4 (pt) |
JP (1) | JP2016517278A (pt) |
KR (1) | KR102527259B1 (pt) |
CN (1) | CN105612253A (pt) |
AU (1) | AU2014229051B2 (pt) |
BR (1) | BR112015021884A8 (pt) |
CA (1) | CA2904156C (pt) |
HK (1) | HK1220488A1 (pt) |
IL (1) | IL240761B2 (pt) |
MX (1) | MX2015012454A (pt) |
RU (1) | RU2725813C2 (pt) |
WO (1) | WO2014144486A2 (pt) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3151866B1 (en) | 2014-06-09 | 2023-03-08 | Voyager Therapeutics, Inc. | Chimeric capsids |
EP3215191A4 (en) | 2014-11-05 | 2018-08-01 | Voyager Therapeutics, Inc. | Aadc polynucleotides for the treatment of parkinson's disease |
CN114717264A (zh) | 2014-11-14 | 2022-07-08 | 沃雅戈治疗公司 | 治疗肌萎缩性侧索硬化(als)的组合物和方法 |
JP6863891B2 (ja) | 2014-11-14 | 2021-04-21 | ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. | 調節性ポリヌクレオチド |
PT3224376T (pt) | 2014-11-28 | 2019-10-25 | Uniqure Ip Bv | Impurezas de dna numa composição compreendendo um vírus parvoviral. |
US11697825B2 (en) | 2014-12-12 | 2023-07-11 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scAAV |
WO2016115503A1 (en) * | 2015-01-16 | 2016-07-21 | Voyager Therapeutics, Inc. | Central nervous system targeting polynucleotides |
US11103597B2 (en) * | 2015-05-14 | 2021-08-31 | St. Jude Children's Research Hospital, Inc. | Nucleic acid molecules containing spacers outside ITR |
CA3001594A1 (en) | 2015-10-14 | 2017-04-20 | Audentes Therapeutics, Inc. | Nucleic acid molecules containing spacers and methods of use thereof |
SG10201912763QA (en) | 2015-11-05 | 2020-02-27 | Bamboo Therapeutics Inc | Modified friedreich ataxia genes and vectors for gene therapy |
IL259964B (en) * | 2015-12-15 | 2022-09-01 | Genzyme Corp | Adenovirus-associated vectors for the treatment of mucolipodosis type ii |
US11155817B2 (en) | 2016-03-18 | 2021-10-26 | The Children's Hospital Of Philadelphia | Therapeutic for treatment of diseases including the central nervous system |
US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
WO2017201258A1 (en) | 2016-05-18 | 2017-11-23 | Voyager Therapeutics, Inc. | Compositions and methods of treating huntington's disease |
BR112018073384A2 (pt) | 2016-05-18 | 2019-03-06 | Voyager Therapeutics, Inc. | polinucleotídeos moduladores |
CN106344932B (zh) * | 2016-08-26 | 2019-12-27 | 首都医科大学附属北京同仁医院 | 一种用于提高视网膜退行性疾病基因治疗效果的组合物及其应用 |
EP3506817A4 (en) | 2016-08-30 | 2020-07-22 | The Regents of The University of California | METHOD FOR BIOMEDICAL TARGETING AND RELEASE, AND DEVICES AND SYSTEMS FOR IMPLEMENTING THEM |
JP7211960B2 (ja) | 2017-03-01 | 2023-01-24 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 眼疾患の遺伝子治療 |
EP3613856A4 (en) * | 2017-03-31 | 2020-12-23 | Staidson(Beijing) Biopharmaceuticals Co., Ltd. | SHRNA EXPRESSION CASSETTE, POLYNUCLEOTIDE SEQUENCE THEREOF AND THEIR APPLICATION |
EA201992358A1 (ru) | 2017-04-03 | 2020-03-24 | Инкоудид Терапьютикс, Инк. | Тканеселективная экспрессия трансгена |
WO2018204786A1 (en) | 2017-05-05 | 2018-11-08 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
US11752181B2 (en) | 2017-05-05 | 2023-09-12 | Voyager Therapeutics, Inc. | Compositions and methods of treating Huntington's disease |
JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
JP7229989B2 (ja) | 2017-07-17 | 2023-02-28 | ボイジャー セラピューティクス インコーポレイテッド | 軌道アレイガイドシステム |
US20200237799A1 (en) | 2017-10-16 | 2020-07-30 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
WO2019079240A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
US10610606B2 (en) | 2018-02-01 | 2020-04-07 | Homology Medicines, Inc. | Adeno-associated virus compositions for PAH gene transfer and methods of use thereof |
EP3755795A4 (en) | 2018-02-19 | 2022-07-20 | Homology Medicines, Inc. | ADENO-ASSOCIATED VIRUS COMPOSITIONS FOR RECOVERING F8 GENE FUNCTION AND METHODS OF USE THEREOF |
MA51353B1 (fr) * | 2018-04-05 | 2022-09-30 | Univ Sorbonne | Sérotype du virus adéno-associé recombinant hybride entre aav9 et aavrh74 possédant un tropisme hépatique réduit |
EP3818161A1 (en) * | 2018-07-02 | 2021-05-12 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord |
AU2019363593A1 (en) * | 2018-10-25 | 2021-04-29 | Takeda Pharmaceutical Company Limited | AAV triple-plasmid system |
TW202039856A (zh) * | 2019-03-28 | 2020-11-01 | 西班牙商艾斯提夫製藥股份有限公司 | 製造重組病毒載體之方法 |
EP4051790A4 (en) * | 2019-10-31 | 2023-11-01 | William Marsh Rice University | GENETICALLY ENGINEERED CELLS FOR CONTROLLED PRODUCTION |
TW202140791A (zh) | 2020-01-13 | 2021-11-01 | 美商霍蒙拉奇醫藥公司 | 治療苯酮尿症之方法 |
RU2733361C1 (ru) * | 2020-07-14 | 2020-10-01 | Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) | Средство для ингибирования репликации вируса SARS-CoV-2, опосредованного РНК-интерференцией |
JP2023548816A (ja) | 2020-11-03 | 2023-11-21 | ファイザー・インク | 陰イオン交換クロマトグラフィーによるaavベクターの精製方法 |
AU2021404944A1 (en) | 2020-12-23 | 2023-07-06 | Pfizer Inc. | Methods for purification of aav vectors by affinity chromatography |
WO2022170146A1 (en) * | 2021-02-05 | 2022-08-11 | Maze Therapeutics, Inc. | Vectors comprising stuffer polynucleotide sequences |
RU2746362C9 (ru) * | 2021-03-11 | 2021-04-26 | Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) | Комбинированное лекарственное средство, обладающее противовирусным эффектом в отношении нового коронавируса SARS-CoV-2 |
WO2023114816A1 (en) | 2021-12-14 | 2023-06-22 | Neurogene, Inc. | Recombinant optimized galc constructs and methods for treating galc-associated disorders |
GB202201242D0 (en) | 2022-01-31 | 2022-03-16 | Univ Edinburgh | Recombinant optimized mecp2 cassettes and methods for treating rett syndrome and related disorders |
GB202206336D0 (en) | 2022-04-29 | 2022-06-15 | Univ Edinburgh | Recombinant therapeutic FMR1 constructs and methods of treating fragile X syndrome and related disorders |
WO2024003687A1 (en) | 2022-06-28 | 2024-01-04 | Pfizer Inc. | Nucleic acids encoding acid alpha-glucosidase (gaa) and vectors for gene therapy |
CN114990162A (zh) * | 2022-07-18 | 2022-09-02 | 苏州吉纳星辰生物技术有限公司 | 一种降低aav病毒载体生产中质粒残留的方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6294379B1 (en) * | 1998-02-25 | 2001-09-25 | The Regents Of The University Of California | Efficient AAV vectors |
US6521426B1 (en) * | 1998-04-08 | 2003-02-18 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Preparation of recombinant adenovirus carrying a rep gene of adeno-associated virus |
EP1369491A1 (en) | 2002-06-05 | 2003-12-10 | Aladar A. Szalay | Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue |
EP1979485A2 (en) | 2006-01-31 | 2008-10-15 | The Board Of Trustees Of The Leland Stanford Junior University | Self-complementary parvoviral vectors, and methods for making and using the same |
US8129510B2 (en) * | 2006-03-30 | 2012-03-06 | The Board Of Trustees Of The Leland Stanford Junior University | Minigene expression cassette |
CA2921594A1 (en) | 2006-06-21 | 2007-12-27 | Uniqure Ip B.V. | Aav vectors with improved rep coding sequences for production in insect cells |
WO2012158757A1 (en) | 2011-05-16 | 2012-11-22 | The Trustees Of The University Of Pennsylvania | Proviral plasmids for production of recombinant adeno-associated virus |
JP6373763B2 (ja) | 2012-02-17 | 2018-08-22 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia | Aavベクター成分、及び、細胞、臓器並びに組織への遺伝子導入のための方法 |
-
2014
- 2014-03-14 KR KR1020157029723A patent/KR102527259B1/ko active IP Right Grant
- 2014-03-14 WO PCT/US2014/028911 patent/WO2014144486A2/en active Application Filing
- 2014-03-14 BR BR112015021884A patent/BR112015021884A8/pt not_active Application Discontinuation
- 2014-03-14 US US14/776,630 patent/US11427835B2/en active Active
- 2014-03-14 CA CA2904156A patent/CA2904156C/en active Active
- 2014-03-14 AU AU2014229051A patent/AU2014229051B2/en active Active
- 2014-03-14 CN CN201480016235.8A patent/CN105612253A/zh active Pending
- 2014-03-14 MX MX2015012454A patent/MX2015012454A/es unknown
- 2014-03-14 JP JP2016502935A patent/JP2016517278A/ja active Pending
- 2014-03-14 EP EP14763615.3A patent/EP2970943A4/en active Pending
- 2014-03-14 RU RU2015144047A patent/RU2725813C2/ru active
-
2015
- 2015-08-23 IL IL240761A patent/IL240761B2/en unknown
-
2016
- 2016-07-18 HK HK16108471.3A patent/HK1220488A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP2970943A2 (en) | 2016-01-20 |
CN105612253A (zh) | 2016-05-25 |
CA2904156A1 (en) | 2014-09-18 |
US20160032319A1 (en) | 2016-02-04 |
HK1220488A1 (zh) | 2017-05-05 |
IL240761A (en) | 2015-10-29 |
AU2014229051B2 (en) | 2020-07-16 |
RU2015144047A (ru) | 2017-04-27 |
KR102527259B1 (ko) | 2023-04-27 |
BR112015021884A2 (pt) | 2017-07-18 |
WO2014144486A2 (en) | 2014-09-18 |
KR20160026841A (ko) | 2016-03-09 |
IL240761B2 (en) | 2023-05-01 |
WO2014144486A3 (en) | 2014-11-06 |
US11427835B2 (en) | 2022-08-30 |
RU2725813C2 (ru) | 2020-07-06 |
EP2970943A4 (en) | 2017-04-19 |
MX2015012454A (es) | 2016-04-25 |
AU2014229051A1 (en) | 2015-09-10 |
JP2016517278A (ja) | 2016-06-16 |
IL240761B1 (en) | 2023-01-01 |
CA2904156C (en) | 2023-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015021884A8 (pt) | vetores de plasmídeo recombinantes, partícula viral avv ou pluralidade de partículas virais, seus métodos de produção e seus usos, e composição farmacêutica | |
PH12019500694A1 (en) | Factor viii compositions and methods of making and using the same | |
MX2021004294A (es) | Suministro mejorado de particulas virales al cuerpo estriado y al cortex. | |
ECSP17074016A (es) | Producción de vectores adeno-asociados de gran tamaño | |
SA517381912B1 (ar) | "عناصر تنظيمية معدلة بعد الانتساخ لعلاج الالتهاب الكبدي pre | |
MX2021006931A (es) | Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos. | |
MX2017004039A (es) | Fosforamiditas de n-acetilgalactosamina (galnac), conjugados de acido nucleico de las mismas y su uso. | |
BR112016028023A2 (pt) | Composições e métodos de administração de tratamentos para infecções virais latentes | |
BR112015022208A2 (pt) | proteínas de fusão que compreendem pdgf e partes de ligação de vegf, seu método de produção bem como seus usos, composição, ácido nucleico, célula hospedeira, vetor, partícula de raav e seu método de produção | |
WO2013078199A3 (en) | Methods for enhanced in vivo delivery of synthetic, modified rnas | |
MX2021010668A (es) | Proteinas de fusion de citoquinas. | |
BR112016015187A2 (pt) | proteína de fusão para inibição da angiogênese ou do crescimento e uso da mesma | |
BR112017004770A2 (pt) | partícula tipo flavivírus | |
WO2015054439A3 (en) | Hybrid factor viii polypeptides for use to treat hemophilia a | |
MX2018007330A (es) | Vectores virales adeno-asociados para tratar mucolipidosis de tipo ii. | |
BR112017008152A2 (pt) | promotor recombinante com expressão específica de fibra aumentada | |
BR112015022885A2 (pt) | composições de promotor | |
MX365656B (es) | Nuevas vacunas contra multiples subtipos del virus del dengue. | |
BR112016021017A2 (pt) | Partículas de raav, composição e uso das mesmas na terapia gênica para retinite pigmentosa | |
MY185444A (en) | Enterovirus 71 antiviral peptides | |
MX352456B (es) | Lotes de adenovirus recombinantes con extremos alterados. | |
AR100577A1 (es) | Medios y métodos para el tratamiento de cmv | |
MX2015011064A (es) | Vacuna contra el virus de la leucemia bovina. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] |